<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269658</url>
  </required_header>
  <id_info>
    <org_study_id>P08636</org_study_id>
    <secondary_id>P08636</secondary_id>
    <nct_id>NCT01269658</nct_id>
  </id_info>
  <brief_title>A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)</brief_title>
  <official_title>A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of azithromycin ophthalmic
      solution, 1% versus vehicle over a four-week treatment period in treating the signs and
      symptoms of subjects with blepharitis and to evaluate the clinical course of the condition
      under study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of clinical signs of blepharitis</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first clinical resolution</measure>
    <time_frame>Days 7, 14, 21, 28, 42, 56, 70, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and change from baseline for clinical signs of blepharitis</measure>
    <time_frame>Days 7, 14, 21, 28, 42, 56, 70, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and change from end of dosing for clinical signs of blepharitis</measure>
    <time_frame>Days 42, 56, 70, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to the Blepharitis Symptoms Questionnaire (BSQ)</measure>
    <time_frame>Days 1, 7, 14, 21, 28, 42, 56, 70, and 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Azithromycin ophthalmic solution, 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin ophthalmic solution, 1%</intervention_name>
    <description>1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)</description>
    <arm_group_label>Azithromycin ophthalmic solution, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a current diagnosis of blepharitis

          -  Have a best corrected visual acuity (BCVA), using corrective lenses if

        necessary, in both eyes of at least +0.7

          -  If female, are non-pregnant or non-lactating

        Exclusion Criteria:

          -  Have a concurrent acute hordeolum (stye) or chalazion

          -  Have inflammation of the ocular surface

          -  Have used artificial tears within 48 hours prior to Visit 1 or anticipate

        using during the study

          -  Have had ocular surgery in the past 90 days or will require it during the

        study

          -  Unable to withhold the use of contact lenses during the study

          -  Have a known hypersensitivity to azithromycin, erythromycin, any other

        macrolide antibiotic, or any of the other ingredients in the study

        medication

          -  Have been diagnosed with ongoing glaucoma

          -  Unable to withhold the use of ocular cosmetic products within 48 hours

        prior to Visit 1 and throughout the study

          -  Have a serious medical condition which could confound study assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Johnson, MBChB</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <disposition_first_submitted>July 6, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 6, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2011</disposition_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

